Latest chemotherapy Stories
HAMPTON, Va., Oct. 4, 2012 /PRNewswire-iReach/ -- Told he had lung cancer and 6 months to live, the author refused chemo/surgery and used holistic, natural, non-invasive interventions. Now, 38 years later at age 80 he not only beat the odds of lung cancer but also the odds of 3 chronic illnesses and 5 prescribed medications that are the average for a 75 year old. The goal of the author is to empower others to prevent/overcome lung cancer and remain disease free into later life using...
Recipients of hematopoietic cell transplants (HCT) are at an increased risk of developing heart disease risk factors such as high blood pressure, diabetes, and high cholesterol. Long-term survivors of HCT with multiple heart disease risk factors treated with chemotherapy or radiation prior to HCT have an especially high risk of developing heart disease. WASHINGTON, Oct. 3, 2012 /PRNewswire-USNewswire/ -- New research appearing online today in Blood, the Journal of the American...
Phase III data reported at ESMO 2012 New trial data showing improvements in the treatment of esophageal and gastrointestinal cancers were released today at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna. Phase III, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing after chemotherapy The first phase III trial to address the need for second-line treatments in esophageal cancer shows that...
VIENNA, Sept. 30, 2012 /PRNewswire/ -- Additional data from pre-specified interim analyses of COU-AA-302, a Phase 3, randomized, placebo-controlled study, suggested ZYTIGA(®) (abiraterone acetate) plus prednisone, compared to placebo plus prednisone, delayed pain progression and functional decline in asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) patients whose disease progressed after androgen deprivation therapy and anti-androgens....
RIDGEFIELD, Conn., Sept. 28, 2012 /PRNewswire/ -- Boehringer Ingelheim today announced new patient-reported health-related outcomes for its investigational oncology compound afatinib,* including lung cancer-related symptoms and quality of life (QoL). These data are secondary endpoints of LUX-Lung 3, a Phase III trial of afatinib (n=230) compared to chemotherapy (pemetrexed/cisplatin) (n=115) in patients with epidermal growth factor receptor (EGFR) mutation-positive advanced...
BOTHELL, Wash. and VANCOUVER, British Columbia, Sept. 27, 2012 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the initiation of ENSPIRIT, a Phase 3 trial evaluating custirsen for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) in patients who have progressed after initial chemotherapy treatment has failed. The trial will investigate if combining custirsen with docetaxel, a standard second-line NSCLC chemotherapy, has the...
Films that feature characters with cancer have become a familiar sight for movie-goers in recent years, but they rarely portray the patient's chances of survival accurately, Italian researchers will report at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna, Austria. After carefully studying 82 movies that center on a person with cancer, from Cat on a Hot Tin Roof, and Gran Torino to Diary of a Country Priest and beyond, Dr Luciano De Fiore from Sapienza...
BETHESDA, Md., Sept. 20, 2012 /PRNewswire/ -- Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for cancer, announced today that it is in late stage discussions with medical centers in the U.S. and Europe to proceed with a Phase I/II clinical trial with the Company's third major product line, DCVax(®)-Direct, for all types of solid tumor cancers (i.e., cancers in any tissues). The Company previously received...
A new study published in The Oncologist found that genetically engineered mouse models appear to be the most accurate preclinical predictor of how cancer-fighting drugs are delivered to melanoma patients. The study, led by UNC-Chapel Hill researchers along with colleagues in the Research Triangle Park, Pittsburgh and Austria, tested how four different types of mouse models predict the delivery of carboplatin, a commonly used anticancer drug, to melanoma tumors in patients. Durham, NC...
At St. Jude Children’s Research Hospital, patients use beads to mark treatment milestones, from losing their hair to completing chemotherapy, in a program other hospitals could tailor to meet the needs of their patients When Kayla Dehnert tells friends and family in Northern California about life as a St. Jude Children’s Research Hospital patient, she pulls out a string of beads taller than she is. “This is a learning-to-take medicine bead,” Kayla explains, fingering the bumps...
Latest chemotherapy Reference Libraries
Intravenous therapy, commonly known as IV therapy, is known as the administration of a liquid substance directly into a vein. It is also known as drip therapy, because most often the liquid is suspended above the IV site by an infusion pump, and runs through a drip chamber, which prevents air from entering the line. IVs are the preferred method of drug administration in hospital settings because they are the fastest known route of getting medication to the body. Intravenous therapy can also...
Antiviral Chemistry & Chemotherapy is a peer-reviewed academic journal published bi-monthly by International Medical Press in London since 1997. When founded in January 1990, it was published by Blackwell Science. The current editor-in-chief is Hugh J. Field of University of Cambridge, UK. The journal publishes primary papers and reviews on all aspects of the preclinical development of antiviral agents, including their chemical synthesis, biochemistry, pharmacology, mode of action and...
